人乳头瘤病毒疫苗的应用与研究进展

doi:10.3760/cma.j.issn.1673422X.2018.02.012

摘要/Abstract

摘要： 人乳头瘤病毒（HPV）是最常见的性传播病毒，预防HPV感染的HPV疫苗接种已经成为宫颈癌的一级预防措施，在全球多个国家及地区实施应用。治疗性HPV疫苗的研制及应用已成为HPV相关疾病研究的热点。

Abstract: The human papillomavirus (HPV) is the most common sexually transmitted virus. HPV vaccine to prevent HPV infection has become a primary preventive measure for cervical cancer and has been applied in many countries and regions around the world. The application of therapeutic HPV vaccine has become a hot point in the research of HPV.

Key words: Papillomavirus vaccines, Uterine cervical neoplasms

刘静, 李胜泽. 人乳头瘤病毒疫苗的应用与研究进展[J]. 国际肿瘤学杂志, 2018, 45(2): 112-114.

LIU Jing, LI Sheng-Ze. Application and research progress of human papillomavirus vaccine[J]. Journal of International Oncology, 2018, 45(2): 112-114.

参考文献

［1］王凯, 王新萍, 管陈安, 等. TCT、HPVDNA及阴道镜检查在宫颈病变中的意义［J］．现代临床医学, 2015, 41(4): 276277, 279. DOI: 10.11851/j.issn.16731557.2015.04.013. ［2］ Piroozmand A, Mostafavi Zadeh SM, Madani A, et al. The association of high risk human papillomaviruses in patients with cervical cancer: an evidence based study on patients with squamous cell dysplasia or carcinoma for evaluation of 23 human papilloma virus genotypes［J］. Jundishapur J Microbiol, 2016, 9(4): e32728. DOI: 10.5812/jjm.32728. ［3］ Cerutti ML, Alonso LG, Tatti S, et al. Longlasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model［J］. Int J Cancer, 2012, 130(8): 18131820. DOI: 10.1002/ijc.26294. ［4］ Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008［J］. Sex Transm Dis, 2013, 40(3): 187193. DOI: 10.1097/OLQ.0b013e318286bb53. ［5］ Schiller JT, Castellsagué X, Garland SM, et al. A review of clinical trials of human papillomavirus prophylactic vaccines［J］. Vaccine, 2012, 30(S5)： F123F138. DOI: 10.1016/j.vaccine.2012.04.108. ［6］ de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study［J］. Lancet Oncol, 2010, 11(11): 10481056. DOI: 10.1016/S14702045(10)702308. ［7］李响, 金文婷, 满玉晶, 等. HPV疫苗预防宫颈癌的应用研究［J］. 生殖医学杂志, 2017, 26(2): 188192. DOI: 10.3969/j.issn.10043845.2017.02.018. ［8］李芹, 刘春容, 李静. 世界范围内9～26岁女性对HPV的认知现状及预防性HPV疫苗的应用现况［J］. 中国肿瘤, 2017, 26(3): 161169. DOI: 10.11735/j.issn.10040242.2017.03.A001. ［9］ Kirby T. FDA approves new upgraded Gardasil 9［J］. Lancet Oncol, 2015, 16(2): e56. DOI： 10.1016/S14702045(14)71191X. ［10］ Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introductionthe first five years［J］. Vaccine, 2012, 30 Suppl 5: F139F148. DOI: 10.1016/j.vaccine.2012.05.039. ［11］王卡娜, 郄明蓉. HPV治疗性疫苗研究现状［J］. 实用妇产科杂志, 2017, 33(2): 8991. ［12］马杰, 赵卫东. 治疗性人乳头瘤病毒疫苗研究进展［J］. 国际免疫学杂志, 2015, 38(2): 181184. DOI： 10.3760/cma.j.issn.16734394.2015.02.019. ［13］ Ma B, Maraj B, Tran NP, et al. Emerging human papillomavirus vaccines［J］. Expert Opin Emerg Drugs, 2012, 17(4): 469492. DOI: 10.1517/14728214.2012.744393. ［14］ Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7pulsed dendritic cell vaccination stage ⅠB or ⅡA cervical cancer patients: a phase Ⅰ escalatingdose trial［J］. J Virol, 2008, 82(4): 19681979. DOI: 10.1128/JVI.0234307. ［15］ Stanley M. Potential mechanisms for HPV vaccineinduced longterm protection［J］. Gynecol Oncol, 2010, 118(1 Suppl): S2S7. DOI: 10.1016/j.ygyno.2010.04.002. ［16］ Draper E, Bissett SL, HowellJones R, et al. A randomized, observerblinded immunogenicity trial of cervarix and gardasil human papillomavirus vaccines in 1215 year old girls［J］. PLoS One, 2013, 8(5): e61825. DOI: 10.1371/journal.pone.0061825. ［17］ Joura EA, Giuliano AR, Iversen OE, et al. A 9valent HPV vaccine against infection and intraepithelial neoplasia in women［J］. N Engl J Med, 2015, 372(8): 711723. DOI: 10.1056/NEJMoa1405044. ［18］ De Vincenzo R, Conte C, Ricci C, et al. Longterm efficacy and safety of human papillomavirus vaccination［J］. Int J Womens Health, 2014, 6: 9991010. DOI: 10.2147/IJWH.S50365. ［19］ Panagiotou OA, Befano BL, Gonzalez P, et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational followup in the Costa Rica HPV Vaccine Trial［J］. BMJ, 2015, 351: h4358. DOI: 10.1136/bmj.h4358. ［20］ Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04adjuvanted vaccine in women older than 25 years: 4year interim followup of the phase 3, doubleblind, randomised controlled VIVIANE study［J］. Lancet, 2014, 384(9961): 22132227. DOI: 10.1016/S01406736(14)60920X. ［21］ Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future CORRIGENDUM［J］. Epidemiol Infect, 2016, 144(11): 2472. DOI: 10.1017/S0950268816000777. ［22］ Macki M, Dabaja AA. Literature review of vaccinerelated adverse events reported from HPV vaccination in randomized controlled trials［J］. Basic Clin Androl, 2016, 26: 16. DOI: 10.1186/S1261001600427. ［23］ Forinash AB, Yancey AM, Pitlick JM, et al. Safety of the HPV bivalent and quadrivalent vaccines during pregnancy［J］. Ann Pharmacother, 2011, 45(2): 258262. DOI: 10.1345/aph.1P396.

[1]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[2]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[3]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[4]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[5]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[6]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[7]	史英侠, 胡莉钧, 于静萍. 免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.
[8]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[9]	熊婵, 阎英, 谢晓冬, 孟繁杰, 于卉影. 辐射诱导的多倍体宫颈癌HeLa细胞生物学特性研究[J]. 国际肿瘤学杂志, 2022, 49(5): 263-269.
[10]	袁晨阳, 周菊英. 宫颈癌预后因素的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 307-313.
[11]	袁晨阳, 周菊英, 杜霄, 纪环, 赵天翼. 宫颈癌2018与2009 FIGO分期的比较及预后因素分析[J]. 国际肿瘤学杂志, 2022, 49(3): 151-163.
[12]	王玥, 吴琼, 许愿, 龚唯, 徐晓婷. 老年宫颈癌的筛查与治疗进展[J]. 国际肿瘤学杂志, 2022, 49(12): 754-758.
[13]	马秀珍, 卢艳, 赵冰冰, 邱宏聪, 徐勋, 韦敏. 岗松总黄酮对宫颈癌SiHa细胞迁移、侵袭及凋亡的影响[J]. 国际肿瘤学杂志, 2021, 48(4): 206-211.
[14]	牛雯娟, 段文杰, 苏雅婷, 魏芳. 对2018年国际妇产联盟宫颈癌新分期的思考[J]. 国际肿瘤学杂志, 2021, 48(10): 627-630.
[15]	于明月, 陈峥峥, 赵旭旭, 任萍萍, 张影, 葛丽, 朱美玲, 赵卫东. 局部晚期宫颈癌术后辅助治疗的影响因素及其列线图风险模型的构建[J]. 国际肿瘤学杂志, 2021, 48(1): 35-40.